FDA Approves Biosimilar Trastuzumab-anns for All Approved Herceptin Indications
On June 13, 2019, Amgen
and Allergan plc
announced the U.S. Food and Drug Administration
) has approved Kanjinti™
(trastuzumab-anns) for all approved indications of the reference product, Herceptin®
(trastuzumab): for the treatment of HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
Read corporate press release